Quantcast Tycoon To Acquire 25% Stake In Sanguibiotech
Search by tag or site Login to my blog ? Start my own blog














TheMoneyBlogs
Home
About
Create your own blog
Contact us
Vote for this blog!

BioHealth Investor

BioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network.

Tycoon To Acquire 25% Stake In Sanguibiotech

Posted on 04/13/2007 10:09:48 | Link | Post Comment
by Sara Calabro
Med Tech Sentinel



Tycoon Venture Capital & Investment of London said today that it would acquire 25% of SanguiBioTech GmbH, a German subsidiary of Sangui BioTech International that makes pharmaceuticals and devices focused on biological regeneration of cells through compensatory supply of vital substrates. As part of the agreement with Tycoon, the venture firm is offering Sangui a mezzanine loan of roughly $10 million. A managing director for the firm said, “We have thoroughly examined the properties and market potential of Sangui’s existing product portfolio, as well as the possible future blockbuster qualities of its haemoglobin polymer blood additive, and we are excited to have the opportunity to participate in the highly promising prospects of this company.”

In addition to the blood additive, SanguiBioTech is hard at work on its GlucoTector product, a long-term implantable glucose sensor for the continuous measurement of glucose levels; the device enables continuous control over three to five years. The sensors are based on optical measuring methods. These methods allow for bloodless and pain-free instant measurement with the advantage of a 24-hour control. The sensors provide data that can be used to analyze patients’ blood glucose levels for a defined period.

SanguiBioTech says the GlucoTector is an improvement over current monitors for the following reasons:

1. It uses at least two independent optical measurement systems in one sensor, which guarantees a high signal reliability and increased sensitivity

2. Measurements of glucose levels are also possible in quantities of less than 40 mg/dL which is significant for the assessment of brain damage

3. Glucose concentration results can be measured from a clearly defined, physically simple system (cuvet measurement).


A more pressing concern among some diabetes sufferers, though, might be: How will it look?



Source: OneMedPlace.com


_____________________
Stock Quote or
Examples
ATM Wallstreet - Tue Jul 08, 2008 02:28PM
Why I traded the stock ME today. I had it on my list fr [read more]
Morpheus Trading - Thu Jul 03, 2008 07:49AM
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Sun Jul 06, 2008 11:00PM
NOTE: Please click on the charts below to enlarge them if [read more]

PREMIER SPONSORED LINKS

Most Visited Blogs | Most Popular Blogs | Most Recent Blogs | Contact Us | Terms and conditions | Privacy Policy

The columns, articles, message board posts and any other features provided on TheMoneyBlogs.com are provided for personal finance, education and investment information and are not to be construed as investment advice. Under no circumstances does the information in this content represent a recommendation to buy, sell or hold any security. The views and opinions expressed in an article or column are the author's own and not necessarily those of TheMoneyBlogs.com and there is no implied endorsement by TheMoneyBlogs.com of any advice or trading strategy. The analysts and employees or affiliates of TheMoneyBlogs.com may hold positions in the stocks or industries discussed here. Your use of this and all information contained on TheMoneyBlogs.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

Copyright © 2008 The Connors Group, Inc.